MA-VERISTAT
Veristat , a scientific-minded, global clinical research organization (CRO), announced today that it transferred its majority ownership from Variance Development Partners to WindRose Health Investors (WindRose). WindRose invests exclusively in healthcare companies and has extensive experience across the healthcare services landscape, including outsourced biopharmaceutical services like Veristat’s.
“As a founder of Veristat, I believe that Veristat has attained the ideal investment partner who understands our philosophy, our values, and the impact we make in clinical research,” stated John P. Balser, Ph.D., President, Co-Founder, and Chief Statistical Officer of Veristat. “WindRose has a track record of successful collaboration, understands the critical nature of the scientific and therapeutic expertise we offer and will bring significant knowledge and a network of advisors to assist us as we continue to evolve.”
WindRose will support Veristat’s continued expansion to meet the needs of its growing client base around the world. This partnership will significantly benefit Veristat by complementing the leadership team with a group of diverse and knowledgeable healthcare advisors who share the same vision, culture, and focus on scientific excellence in clinical research.
“We are excited to enter into this relationship with Veristat,” said CJ Burnes, Partner with WindRose. “The Company’s clinical impact and scientific approach to partnering with companies advancing life-enhancing therapies is impressive. Their market position, stellar reputation, and leadership within biostatistics and ability to design and conduct complex clinical trials is unlike any other we have seen. In partnership with the management team and the founders, WindRose plans to contribute substantial resources to support the execution of Veristat’s strategy.”
“I am confident that our partnership with WindRose will allow Veristat’s continued focus on our core mission of helping sponsors solve the challenges that arise when developing ground-breaking products that improve and save lives through our differentiated approach to designing and executing clinical trials, clinical programs, regulatory submissions, and pharmacovigilance,” stated Patrick Flanagan, Chief Executive Officer of Veristat. “WindRose will provide us the capital and a deep network of relationships and expertise in the biotech and pharmaceutical industry as we strategically grow our company.”
Edgemont Partners acted as financial advisor to Veristat. Nutter McClennen & Fish LLP acted as legal advisor to Veristat, and McDermott Will & Emery LLP acted as legal advisor to WindRose.
About WindRose
WindRose makes equity investments in companies that operate within the services sectors of the healthcare industry. The firm focuses on companies with profitable business models and a demonstrated ability to deliver cost-effective solutions. WindRose manages over $1.2 billion in investments and is currently investing out of its fifth fund. WindRose is based in New York City and invests in companies throughout the United States.
For more information, email WindRose at info@windrose.com .
About Veristat
Veristat , a global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years’ experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared over 100 marketing applications for approval with global regulatory authorities in the last 10 years.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005346/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 622.10.2025 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2025 financial results on Thursday, November 6, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting developme
Diligent and Persefoni Form Strategic Partnership to Support Clients in Navigating Sustainability Reporting With Confidence22.10.2025 12:00:00 CEST | Press release
Diligent, the AI leader in governance, risk and compliance SaaS solutions, and Persefoni AI, Inc., a leading Sustainability Management SaaS and AI platform for companies and financial institutions, today announced a strategic partnership to lead the way in sustainability by ensuring clients have the best tools and support to meet their strategic goals and navigate an increasingly complex sustainability landscape with confidence. As part of the agreement, Diligent will transition its carbon accounting clients to Persefoni’s market-leading platform and take an equity position in Persefoni, reinforcing a long-term commitment to innovation in ESG. This partnership ensures Diligent clients benefit from best-in-class capabilities in carbon footprint management, including advanced Scope 3 supply chain sustainability solutions and AI-powered disclosure readiness. "Diligent is committed to providing our customers with the best solutions available to meet today’s needs while preparing for tomorr
Aeroporti di Roma Transforms Passenger Experience with AI Virtual Assistant Powered by Amazon Web Services and Storm Reply22.10.2025 11:32:00 CEST | Press release
The new AI solution provides real-time flight information, baggage status, and personalized support for travelers at Rome Fiumicino Airport Aeroporti di Roma (ADR) announces the launch of Virtual Assistant, an advanced AI-powered digital companion designed to enhance the travel experience for the millions of passengers who pass through Rome Fiumicino Airport each year, recently confirmed by ACI Europe as the Best Airport in Europe for the seventh time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022666853/en/ The Virtual Assistant is now available to all passengers traveling for all the flights to and from Rome Fiumicino airport, with additional features planned for rollout in the coming months. Developed in collaboration with Amazon Web Services (AWS) and Storm Reply, this cutting-edge solution addresses travelers’ most pressing needs by delivering real-time information and support. The Virtual Assistant offers passen
Chelsea Football Club and FPT Elevate and Expand Partnership to Principal Status22.10.2025 11:12:00 CEST | Press release
Chelsea Football Club and FPT today announce an expansion to their existing partnership, which sees Asia Pacific’s most successful technology solutions provider named as a Principal Partner for the 2025/26 season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251017778664/en/ As a Principal Partner, FPT will be represented on the sleeves of the Chelsea FC men’s, women’s, and academy kits. The market-leading digital technology solutions provider FPT and Chelsea FC first joined forces earlier this year in a new and innovative collaboration to transform the club’s digital capabilities and enhance the club’s fan engagement, bringing fans from across the world closer to the club. Through several technology workshops at FPT’s innovation campus in Vietnam, Chelsea FC and FPT have identified and built a transformation roadmap that covers Digital Platforms, Customer Engagement, Business Operations, and Emerging Technologies. With a
Paymentology Launches PayCredit to Power Credit Innovation for Digital Banks and Fintechs22.10.2025 10:00:00 CEST | Press release
The new credit solution integrates card issuing and credit ledger management, helping issuers reduce complexity and accelerate time to market. Paymentology, the leading global issuer-processor, has launched PayCredit, an advanced credit ledger platform designed to help financial institutions deliver tailored, feature rich credit products at speed, overcoming the limitations of legacy and core banking systems. Amid rising demand for flexible financial payment tools, credit cards remain a critical instrument for enabling consumer spending, managing cash flow, and deepening customer loyalty. Yet many legacy credit systems lack the flexibility to meet the expectations of today's consumers, who demand a combination of both revolving and instalment credit to help them better manage their money, whilst many modern ledgers are retrofitted from a debit architecture and struggle to provide credit processing. PayCredit was developed from the ground up with credit billing cycles and logic at its c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom